Molecular dynamics simulations in drug discovery and pharmaceutical development

OMH Salo-Ahen, I Alanko, R Bhadane, AMJJ Bonvin… - Processes, 2020 - mdpi.com
Molecular dynamics (MD) simulations have become increasingly useful in the modern drug
development process. In this review, we give a broad overview of the current application …

RAS proteins and their regulators in human disease

DK Simanshu, DV Nissley, F McCormick - Cell, 2017 - cell.com
RAS proteins are binary switches, cycling between ON and OFF states during signal
transduction. These switches are normally tightly controlled, but in RAS-related diseases …

[HTML][HTML] Exploring the computational methods for protein-ligand binding site prediction

J Zhao, Y Cao, L Zhang - Computational and structural biotechnology …, 2020 - Elsevier
Proteins participate in various essential processes in vivo via interactions with other
molecules. Identifying the residues participating in these interactions not only provides …

Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view

S Lu, H Jang, S Gu, J Zhang, R Nussinov - Chemical Society Reviews, 2016 - pubs.rsc.org
Ras proteins are small GTPases, cycling between inactive GDP-bound and active GTP-
bound states. Through these switches they regulate signaling that controls cell growth and …

Along the allostery stream: Recent advances in computational methods for allosteric drug discovery

D Ni, Z Chai, Y Wang, M Li, Z Yu, Y Liu… - Wiley …, 2022 - Wiley Online Library
Allostery is a universal, biological phenomenon in which orthosteric sites are fine‐tuned by
topologically distal allosteric sites triggered by perturbations, such as ligand binding, residue …

Oncogenic K-Ras binds to an anionic membrane in two distinct orientations: a molecular dynamics analysis

P Prakash, Y Zhou, H Liang, JF Hancock, AA Gorfe - Biophysical journal, 2016 - cell.com
K-Ras is a membrane-associated GTPase that cycles between active and inactive
conformational states to regulate a variety of cell signaling pathways. Somatic mutations in K …

Discovery of high-affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding

MJ McCarthy, CV Pagba, P Prakash, AK Naji… - ACS …, 2019 - ACS Publications
Approximately 15% of all human tumors harbor mutant KRAS, a membrane-associated
small GTPase and notorious oncogene. Mutations that render KRAS constitutively active will …

Computational and biochemical characterization of two partially overlapping interfaces and multiple weak-affinity K-Ras dimers

P Prakash, A Sayyed-Ahmad, KJ Cho, DM Dolino… - Scientific reports, 2017 - nature.com
Recent studies found that membrane-bound K-Ras dimers are important for biological
function. However, the structure and thermodynamic stability of these complexes remained …

Driving structure-based drug discovery through cosolvent molecular dynamics: Miniperspective

P Ghanakota, HA Carlson - Journal of medicinal chemistry, 2016 - ACS Publications
Identifying binding hotspots on protein surfaces is of prime interest in structure-based drug
discovery, either to assess the tractability of pursuing a protein target or to drive improved …

Combined physics-and machine-learning-based method to identify druggable binding sites using SILCS-Hotspots

EB Nordquist, M Zhao, A Kumar… - Journal of Chemical …, 2024 - ACS Publications
Identifying druggable binding sites on proteins is an important and challenging problem,
particularly for cryptic, allosteric binding sites that may not be obvious from X-ray, cryo-EM …